advanced search

Welcome: Guest

log in

Targeted Drug Delivery Technologies: Players, products & prospects to 2018 (Volume IV)

Publication Date June 2009
Publisher Espicom
Product Type Report
Pages 118
ISBN Number 978-1-85822-353-7
Product Code ESP00619
Buy this product or for assistance call +44 20 7060 7474

Summary

Targeted Delivery

By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.

Despite considerable advances in drug delivery technologies, there continues to be a high unmet clinical need for safer and better-tolerated drugs. Sub-optimal compliance and failure to persist with drug treatments are important determinants of therapeutic non-response and are of significant cost to healthcare providers. Advanced targeted drug delivery technologies will help to overcome some of these issues by improving pharmacokinetics, increasing tolerability and reducing dose-limiting off-target effects.

The need for targeted delivery platforms is increasing as patients and drug regulators seek to meet these challenges.

Current and future applications

Whilst the majority of targeted delivery systems under evaluation incorporate passive carrier systems, there will be a shift towards the use of actively targeted carriers to increase the therapeutic index of existing and new products. There are significant opportunities for future commercial developments within the pharmaceutical industry.

These include:

  • Cost-effective production of antibodies and antibody fragments for drug targeting;
  • Development of new polymers and biopolymers that may be utilised in the safe and efficient targeted delivery of drugs and pro-drugs into host cells;
  • Development and selective targeting of macromolecules to improve intracellular uptake and tissue specificity;
  • Development of inactive pro-drugs for tissue specific release;
  • Extended product life-cycles through the development of targeted formulations;
  • Identification of new targeting ligands to improve the targeted delivery of small molecules and macromolecules;
  • Utilisation of multiple targeting ligands to address the needs of patient sub-types;
  • Combined technology platforms to develop targeted therapeutics and diagnostics in a single molecule.

A new generation of targeted delivery systems is under development to meet these needs which should provide greater control over the selective targeting of tissue, either with active moieties or inactive moieties which may be activated within the tissue by biological (enzymes), chemical (pH) or physical means (light, ultrasound) in order to release the active agent. The multitude of delivery platforms will lend themselves to the delivery of both small molecules and macromolecules and to a variety of target sites and delivery routes.

This report is part of a major new 4-volume strategic analysis

Drug Delivery Technologies: Players, Products & Prospects to 2018

Focusing on the sectors that are driving growth

  • VOLUME I
  • CONTROLLED- RELEASE
  • VOLUME II
  • NANOTECHNOLOGY
  • VOLUME III
  • NUCLEIC ACID DELIVERY
  • VOLUME IV
  • TARGETED DELIVERY

Unique company & technology evaluation

It is vital that management information is reliable, current and insightful. Today, product and company assessment must be seen in a wider competitive and market environment.

In this report we present a pr?(C)cis on each of the leading delivery specialists and potential new delivery platforms and have identified their key attributes, based on a number of criteria including:

  • Proprietary delivery technology
  • Applications of the delivery technology within the pharmaceutical industry
  • Management/technical expertise of the delivery specialist
  • Competition within the delivery technology sector
  • Products in development/approved utilising the delivery technology

We have established a competitor ratio analysis based on each of the criteria mentioned above. Each criterion attracts an award of up to 10 points, with a maximum score of 50, thus enabling the establishment of an Espicom ""ranking table"" in each segment of the market, dependent on their relative attributes.

Multi-point evaluation and scoring assessment

Pharma drugs that utilise drug delivery systems have been evaluated based on a number of parameters, including:

  • The technology
  • Comparison of delivery platforms within each area including: activated, degradation or diffusion for controlled-release systems; nano-engineered (nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic, dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled delivery; viral or non-viral platforms for nucleic acid delivery and active or passive platforms for targeted delivery systems
  • The application of the technology within a number of therapy areas
  • Route of delivery (oral, parenteral, transdermal, implantable), delivery of small molecules/macromolecules and vaccines, additional features such as bioerodible materials etc
  • The current status of the technology in clinical development or following approval
  • Number of approved and marketed products, clinical or preclinical development candidates, single or multiple products.
  • Competition within the technology arena
  • Alternative drug delivery systems to technologies under evaluation, advantages and disadvantages over competitors.
  • The drug delivery specialist's expertise
  • Number of drug delivery systems in development, strategic alliances, financial position, marketing presence.
  • The product portfolio
  • Drug delivery systems under evaluation, products in development, commercialisation/development partnerships.
  • Potential drug sales
  • Based on key events such as market, competition, patent expiry, time of entry into the market.

About the Author

Dr Cheryl Barton is a highly regarded independent consultant with over 16 years research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for research projects ranging from Alzheimer's disease to schizophrenia. Dr Barton subsequently joined Dutch investment bank ABN Amro NV as a senior equity analyst where she was lead analyst on major pharmaceutical companies such as Roche and Sanofi-Synth?(C)labo, and assessed the potential impact of new drug development on European Stocks.

In 2002, Dr Barton founded a consulting business (www.Pharmavision.co.uk) to provide independent, tailor-made, pharmaceutical thematic research to investment houses and pharmaceutical companies. The research reports combine independent scientific analysis with patient-based models to forecast the potential sales growth of key drugs in clinical development.

Content

  • Executive Summary
  • Introduction
    • Overview of delivery technologies for targeted delivery: past, present & future
      • Leading technology platforms for systemic targeted drug delivery
    • Systemic targeted delivery: motivators & resistors
      • Motivators
        • Systemic targeted delivery technology motivators
      • Resistors
        • Systemic targeted delivery technology resistors
  • Targeted Delivery Technologies
    • Types of systemic targeted delivery platform in development in the pharma industry
      • Targeting ligands
        • Antibody fragment conjugate delivery
        • Antibody-directed enzyme pro-drug targeted delivery
        • Peptide-induced release for targeted delivery
        • Small molecule conjugate delivery
        • Nucleomic mediated targeted intranuclear delivery
        • Cobalamin mediated targeted intracellular delivery
      • Non-biological targeting platforms
        • Magnetically targeted delivery
        • Photosensitive targeted delivery
    • Current therapeutic applications for systemic targeted delivery
    • Leading systemic targeted products in development
      • Approved systemic and targeted drugs
    • Future commercial applications & opportunities
  • Strategies of Drug Delivery Companies
    • Leading targeted drug delivery companies
      • Leading systemic targeted delivery specialists
    • Partnerships & acquisitions
      • Strategic alliances
      • Strategic acquisitions
        • Recent market activity in targeted delivery companies
    • Intellectual Property
      • Targeted drug delivery patents
  • The Targeted Delivery Market
    • Now 2009
      • Approved targeted delivery product sales
    • Future 2018
      • Global targeted-release product sales
      • Novel targeted delivery product sales
  • Competitor Analysis
    • Movers & Shakers: Cutting edge or losing their grip
      • Movers & shakers in targeted drug delivery systems
    • Abraxis Biosciences (www abraxisbio com)
      • Proprietary delivery technology
        • Abraxis Protosphere - nab technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
        • Drug Delivery Technologies: Targeted
      • Products in development/approved utilising the delivery technology
        • Abraxis' product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Abraxis' targeted sales forecasts
      • Competitor Ratio Analysis
      • Access Pharmaceuticals (www accesspharma com)
      • Proprietary delivery technology
        • Cobalamin targeted delivery
        • Schematic of targeted nanoparticle
        • Targeted delivery of cancer subtypes via folate polymer, Vitamin B12 polymer and biotin polymers
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Access Pharmaceuticals' product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Access Pharmaceuticals' sales forecasts
      • Competitor Ratio Analysis
      • ALZA Corporation (www alza com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • ALZA's targeted product pipeline
      • Sales forecasts of products utilising the delivery technology
        • ALZA's drug delivery sales
      • Competitor Ratio Analysis
      • Armagen Technologies (www armagen com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • ArmaGen Technologies' product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Avidimer Therapeutics (www avidimer com)
      • Proprietary delivery technology
        • Targeted avidimer for methotrexate delivery
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Avidimer's product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Calando Pharmaceuticals (www calandopharma com)
      • Proprietary delivery technology
        • Schematic of Cyclosert technology
        • Schematic of RONDEL technology
        • Drug Delivery Technologies: Targeted
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Calando's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Calando's sales forecasts
      • Competitor Ratio Analysis
      • Cell Therapeutics (www ctiseattle com)
      • Proprietary delivery technology
        • CTI's polyglutamate polymer technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • CTI's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • CTI's targeted drug delivery sales
      • Competitor Ratio Analysis
      • Cerulean Pharma Inc (www ceruleanrx com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Cerulean's product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Copernicus Therapeutics (www cgsys com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Copernicus' product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • CytImmune Sciences Inc (www cytimmune com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • CytImmune's' product pipeline
      • Sales forecasts of products utilising the delivery technology
        • CytImmune's sales forecasts
      • Competitor Ratio Analysis
      • Diatos SA (www diatos com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
        • Drug Delivery Technologies: Targeted
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Diatos' product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Diatos' targeted drug delivery sales
      • Competitor Ratio Analysis
      • Enzon Pharmaceuticals, Inc. (www enzon com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Enzon's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Enzon's targeted product sales
      • Competitor Ratio Analysis
      • Endocyte Inc. (www endocyte com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Endocyte's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Endocyte's targeted drug delivery sales
      • Competitor Ratio Analysis
      • Eurand (www eurand com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Eurand's product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Immunogen (www immunogen com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • ImmunoGen's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • ImmunoGen's targeted delivery sales
      • Competitor Ratio Analysis
      • ImaRx Therapeutics (www imarx com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Drug Delivery Technologies: Targeted
        • ImaRx' product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • NanoBioMagnetics, Inc (www nanobmi com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • NanoBioMagnetics' product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Nanobiotix (www nanobiotix com)
      • Proprietary delivery technology
        • Nanobiotix' NanoXray
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Nanobiotix' product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • NanoCarrier (www nanocarrier co jp)
      • Proprietary delivery technology
        • NanoCoat technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • NanoCarrier's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • NanoCarrier's targeted drug delivery sales
      • Competitor Ratio Analysis
      • Nano Interface Technology (www nanointerfacetech com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • NITI's product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Nektar Therapeutics (www nektar com)
      • Proprietary delivery technology
        • Large molecule conjugate delivery
        • Small molecule conjugate delivery
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Nektar's product pipeline
        • Drug Delivery Technologies: Targeted
      • Sales forecasts of products utilising the delivery technology
        • Nektar's targeted sales forecasts
      • Competitor Ratio Analysis
      • NeoPharm (www neopharm com)
      • Proprietary delivery technology
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • NeoPharm's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • NeoPharm's targeted product pipeline
      • Competitor Ratio Analysis
      • Novosom Ag (www novosom com)
      • Proprietary delivery technology
        • Schematic of SMARTICLES mechanism of targeted delivery
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Novosom's product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • PCI Biotech Holding ASA (www pcibiotech com)
      • Proprietary delivery technology
        • Potential applications for improving the delivery of a range of drug types
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • PCI's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • PCI's targeted product sales
      • Competitor Ratio Analysis
      • Quest PharmaTech (www questpharmatech com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Quest PharmaTech's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Quest PharmaTech's targeted product sales
      • Competitor Ratio Analysis
      • Seattle genetics (www seattlegenetics com)
      • Proprietary delivery technology
        • Schematic of ADC's
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Seattle Genetic's product pipeline
        • Drug Delivery Technologies: Targeted
      • Sales forecasts of products utilising the delivery technology
        • Seattle Genetic's targeted delivery sales
      • Competitor Ratio Analysis
      • Spherics, Inc (www spherics com)
      • Proprietary delivery technology
        • Spherics' Oral Targeted Delivery Technologies
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Spheric's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Spheric's product sales
      • Competitor Ratio Analysis
      • Starpharma (www starpharma com)
      • Proprietary delivery technology
        • Starpharma's polyvalent dendrimers
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Starpharma's product pipeline
      • Sales forecasts of products utilising the delivery technology
      • Competitor Ratio Analysis
      • Supratek Pharma Inc. (www supratek com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Supratek's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Supratek's product sales
      • Competitor Ratio Analysis
      • Tekmira Pharmaceuticals Corporation (www tekmirapharm com)
      • Proprietary delivery technology
      • Applications in the pharma industry
      • Management/technical expertise
      • Competition within the delivery technology sector
      • Products in development/approved utilising the delivery technology
        • Tekmira's product pipeline
      • Sales forecasts of products utilising the delivery technology
        • Tekmira's sales forecasts
      • Competitor Ratio Analysis
  • Appendix
    • Global targeted approved drugs sales 2008-2018 (US$ millions)
  • Appendix
    • Global targeted developmental drugs sales 2008-2018 (US$ millions)
  • Appendix
    • Competitor Ratio Analysis Criteria
      • Key targeted delivery companies by 2018
      • Drug Delivery Technologies: Targeted
  • Glossary
  • Acronyms
  • Bibliography
  • Endnotes
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.

PRINT/CD-ROM:Despatched within 1 to 2 working days.

Industry Events

Oncology Market & Patient Access

14 Dec 09 to 16 Dec 09
Prague, Czech Republic
view summary >>

2nd International Conference on Drug Discovery and Therapy

01 Feb 10 to 04 Feb 10
Dubai, United Arab Emirates
view summary >>